MedTrace Logo

γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant

NCT07123662 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-08-14

No results posted yet for this study

Summary

This is a prospective, double-arm, single-center, randomized controlled single-blind clinical study

Conditions

Interventions

BIOLOGICAL

Gamma-Delta T cell injection

Experimental group: Peripheral intravenous infusion of γδ T cells

OTHER

Standard prophylactic treatment

Standard prophylactic treatment

Sponsors & Collaborators

  • Guangzhou Bio-gene Technology Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Donghua Zhang, MD · Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2028-05-30
Completion
2028-05-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07123662 on ClinicalTrials.gov